Phase III trial of tosedostat in elderly patients with high risk myelodysplastic syndromes or secondary acute myeloid leukaemia who have failed to respond adequately to hypomethylating agents.

Trial Profile

Phase III trial of tosedostat in elderly patients with high risk myelodysplastic syndromes or secondary acute myeloid leukaemia who have failed to respond adequately to hypomethylating agents.

Planning
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2016

At a glance

  • Drugs Tosedostat (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Jan 2016 Planned initiation date changed from 1 Dec 2012 to 1 Jan 2016, as per CTI BioPharma media release.
    • 01 Aug 2012 Planned initiation date changed from 1 Jun 2012 to 1 Dec 2012.
    • 13 Dec 2011 Planned initiation date changed from 1 Oct 2011 to 1 Jun 2012, according to a Chroma Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top